Recent studies have shown that p‐tau217 levels strongly correlate with Aβ and tau pathology and cognitive decline, making it a particular and sensitive biomarker for differentiating AD from other neurodegenerative diseases.25, 53. This evidence concerns the gene MAPT and Alzheimer disease.